Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status.

HPV OPSCC TATI survival

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
04 Jun 2021
Historique:
received: 29 04 2021
revised: 30 05 2021
accepted: 02 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

We studied the role of tumor-associated trypsin inhibitor (TATI) in serum and in tumor tissues among human papillomavirus (HPV)-positive and HPV-negative OPSCC patients. The study cohort included 90 OPSCC patients treated at the Helsinki University Hospital (HUS), Helsinki, Finland, in 2012-2016. TATI serum concentrations (S-TATIs) were determined by an immunofluorometric assay. Immunostaining was used to assess tissue expression. HPV status was determined with a combination of p16 immunohistochemistry and HPV DNA PCR genotyping. The survival endpoints were overall survival (OS) and disease-specific survival (DSS). A significant correlation was found between S-TATI positivity and poor OS ( Our results suggest that S-TATI positivity may be a biomarker of poor prognosis in both HPV-positive and HPV-negative OPSCC.

Sections du résumé

BACKGROUND BACKGROUND
We studied the role of tumor-associated trypsin inhibitor (TATI) in serum and in tumor tissues among human papillomavirus (HPV)-positive and HPV-negative OPSCC patients.
MATERIALS AND METHODS METHODS
The study cohort included 90 OPSCC patients treated at the Helsinki University Hospital (HUS), Helsinki, Finland, in 2012-2016. TATI serum concentrations (S-TATIs) were determined by an immunofluorometric assay. Immunostaining was used to assess tissue expression. HPV status was determined with a combination of p16 immunohistochemistry and HPV DNA PCR genotyping. The survival endpoints were overall survival (OS) and disease-specific survival (DSS).
RESULTS RESULTS
A significant correlation was found between S-TATI positivity and poor OS (
CONCLUSION CONCLUSIONS
Our results suggest that S-TATI positivity may be a biomarker of poor prognosis in both HPV-positive and HPV-negative OPSCC.

Identifiants

DOI: 10.3390/cancers13112811 PMID: 34199993 PMC: PMC8200219
pubmed: 34199993
pii: cancers13112811
doi: 10.3390/cancers13112811
pmc: PMC8200219
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Sigrid Juséliuksen Säätiö
ID : 4

Références

Scand J Gastroenterol. 2013 Sep;48(9):1066-73
pubmed: 23889187
Acta Otorhinolaryngol Ital. 2014 Oct;34(5):299-309
pubmed: 25709145
Histopathology. 2005 Apr;46(4):380-8
pubmed: 15810949
Int J Cancer. 1999 Nov 12;83(4):486-90
pubmed: 10508484
Anticancer Res. 2011 May;31(5):1515-9
pubmed: 21617204
Int J Cancer. 2007 Dec 1;121(11):2465-72
pubmed: 17680565
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Br J Cancer. 2017 Sep 5;117(6):856-866
pubmed: 28751758
Virchows Arch. 2018 Jun;472(6):975-981
pubmed: 29721609
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
J Pathol. 2006 Jun;209(2):147-56
pubmed: 16691544
Cancer. 2020 Jun 1;126(11):2658-2665
pubmed: 32129894
Clin Chem. 2016 Mar;62(3):449-57
pubmed: 26656134
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Eur Urol. 2007 Dec;52(6):1670-9
pubmed: 17306443
Int J Cancer. 1982 Jul 15;30(1):53-7
pubmed: 6811446
J Clin Pathol. 2019 Aug;72(8):542-549
pubmed: 31113825
Laryngoscope. 2016 Apr;126(4):894-900
pubmed: 26845348
Nat Commun. 2020 Jan 20;11(1):384
pubmed: 31959826
Anticancer Res. 2015 Jul;35(7):3801-10
pubmed: 26124325
Int J Cancer. 2020 Apr 15;146(8):2166-2174
pubmed: 31269236
J Natl Cancer Inst. 2008 Mar 19;100(6):407-20
pubmed: 18334711
J Clin Oncol. 2019 Jun 20;37(18):1578-1589
pubmed: 31021656
Cancer Immunol Immunother. 2020 Aug;69(8):1615-1626
pubmed: 32314041
J Immunol Methods. 1993 May 5;161(1):97-106
pubmed: 8486933
Scand J Urol. 2020 Oct;54(5):413-419
pubmed: 32748674
Clin Chim Acta. 2014 Apr 20;431:260-9
pubmed: 24583226
Br J Cancer. 2009 May 19;100(10):1540-8
pubmed: 19384300
Tumour Biol. 2016 Jul;37(7):9367-74
pubmed: 26779635
Cancer. 1993 Mar 15;71(6):1982-8
pubmed: 8443749
Hum Pathol. 2019 Aug;90:97-105
pubmed: 31121191
Eur Arch Otorhinolaryngol. 2011 Jan;268(1):5-16
pubmed: 20827554
Acta Otolaryngol. 2018 May;138(5):513-518
pubmed: 29161981
BMC Cancer. 2010 Sep 17;10:498
pubmed: 20849596
J Otolaryngol Head Neck Surg. 2018 Sep 6;47(1):53
pubmed: 30189895
Nat Commun. 2018 Oct 17;9(1):4315
pubmed: 30333494
Urology. 2003 Aug;62(2):249-53
pubmed: 12893328
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
Oral Oncol. 2017 Sep;72:38-47
pubmed: 28797460
Hoppe Seylers Z Physiol Chem. 1978 Jun;359(6):671-5
pubmed: 669578
Clin Transl Gastroenterol. 2018 Nov 12;9(11):204
pubmed: 30420730
Oral Oncol. 2016 Oct;61:12-8
pubmed: 27688099
J Oral Pathol Med. 2017 Feb;46(2):82-88
pubmed: 27237745
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Gastroenterol Hepatol. 2011 Aug;23(8):633-41
pubmed: 21654320
Mol Cancer Res. 2018 Jan;16(1):90-102
pubmed: 28928286
J Dent Res. 2002 Dec;81(12):831-5
pubmed: 12454097
Genes Dev. 2010 Nov 15;24(22):2463-79
pubmed: 21078816
Anal Bioanal Chem. 2018 Feb;410(6):1679-1688
pubmed: 29318362

Auteurs

Anni Sjöblom (A)

Department of Pathology, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 21, FI-00014 Helsinki, Finland.
ORCID: 0000-0003-1740-4346

Ulf-Håkan Stenman (UH)

Department of Clinical Chemistry, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 63, FI-00014 Helsinki, Finland.

Jaana Hagström (J)

Department of Pathology, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 21, FI-00014 Helsinki, Finland.
Research Programs Unit, Translational Cancer Biology, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.
Department of Oral Pathology and Oral Radiology, University of Turku, Lemminkäisenkatu 2, FI-20520 Turku, Finland.

Lauri Jouhi (L)

Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 263, FI-00029 Helsinki, Finland.

Caj Haglund (C)

Research Programs Unit, Translational Cancer Biology, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.
Department of Surgery, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 440, FI-00029 Helsinki, Finland.

Stina Syrjänen (S)

Department of Oral Pathology and Oral Radiology, University of Turku, Lemminkäisenkatu 2, FI-20520 Turku, Finland.
Department of Pathology, Turku University Hospital, Kiinamyllynkatu 10, FI-20520 Turku, Finland.
ORCID: 0000-0003-0738-5698

Petri Mattila (P)

Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 263, FI-00029 Helsinki, Finland.

Antti Mäkitie (A)

Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 263, FI-00029 Helsinki, Finland.
Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska Hospital, SE-171 76 Stockholm, Sweden.
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.
ORCID: 0000-0002-0451-2404

Timo Carpén (T)

Department of Pathology, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 21, FI-00014 Helsinki, Finland.
Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 263, FI-00029 Helsinki, Finland.
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.

Classifications MeSH